摘要
目的研究ERα阳性表达的乳腺癌组织中ERβ蛋白与C-erbB-2蛋白表达情况,探讨ERβ亚型表达的变化与内分泌治疗抵抗之间的关系,为乳腺癌临床内分泌治疗方案的确定提供更确切的理论依据。方法对83例乳腺癌患者,用免疫组化法检测组织中ERα的表达,同时检测ERα阳性组织中原癌蛋白C-erbB-2及ERβ表达的变化。结果48例ERα阳性的乳腺癌组织中,C-erbB-2表达阳性者,ERβ的表达量显著升高(P<0.001)。结论ERβ高表达与内分泌治疗的耐药表现有关,检测ERβ的表达水平可作为另一预测内分泌治疗效果的有用指标。
Objective To analyze the expression of ERβ and C-erbB-2 in ERα positive breast cancer, and to study the relationship between ERβ and endocrine therapy resistance, in order to provide scientific basis for endocrine therapy. Methods Using immunochemistry to determine the expression of ERα in 83 breast cancer patients and the expression of ERβ and C-erbB-2 in ERα positive tissues. Results The relative expression of ERβ was significantly up-regulated in the C-erbB-2 positive group as compared with the C-erbB-2 negative group（P 〈0.001）. Conclusion These results suggested that the role of ERβ is important during breast tumorigenesis, the importance of up-regulated ERβ in tamoxifen resistance was validated and study the expression of ERβ is a new way in determining the result of endocrine therapy, these result may lead further support on therapy and prognostic factor in breast cancer.
出处
《肿瘤研究与临床》
CAS
2006年第1期19-20,共2页
Cancer Research and Clinic
